TITLE

bmj updates

PUB. DATE
August 2006
SOURCE
BMJ: British Medical Journal (International Edition);8/12/2006, Vol. 333 Issue 7563, preceding p311
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article provides a summary of the article "Parathyroid hormone for the treatment of osteoporosis: a systematic review," by A. Cranney, et al. The study evaluated the use of parathyroid hormone as a treatment for osteoporosis in women. The research found that the use of parathyroid hormone increases bone mineral density and reduces the risk of bone fractures associated with osteoporosis. Details of the research study's methodology and findings are provided.
ACCESSION #
22018069

 

Related Articles

  • Recombinant Full-Length Parathyroid Hormone (1-84). Moen, Marit D.; Scott, Lesley J // BioDrugs;2007, Vol. 21 Issue 3, p205 

    The article discusses the importance of recombinant full-length parathyroid hormone in treating osteoporosis. Osteoporosis occurs when the rate of bone resorption exceeds the rate of bone formation. The resulting loss of bone mass and strength can lead to fragility fractures. Available...

  • Parathyroid Hormone as an Anabolic Skeletal Therapy. Rubin, Mishaela R.; Bilezikian, John P. // Drugs;2005, Vol. 65 Issue 17, p2481 

    The quest for effective treatment for osteoporosis merits great attention because of the widespread prevalence of this disease, which is not only associated with fragility fractures, but also with significant morbidity and mortality. The efficacy of the antiresorptive drugs in this disease is...

  • Emerging therapeutic opportunities for skeletal restoration. Kawai, Masanobu; Mödder, Ulrike I.; Khosla, Sundeep; Rosen, Clifford J.; Mödder, Ulrike I // Nature Reviews Drug Discovery;Feb2011, Vol. 10 Issue 2, p141 

    Osteoporosis, a syndrome characterized by thin bones and fractures, has become more prevalent in both women and men. Established therapies for treating this disorder consist primarily of drugs that prevent bone loss, such as the bisphosphonates and selective oestrogen receptor modulators....

  • A Fracture Does Not Adversely Affect Bone Mineral Density Responses after Teriparatide Treatment. Unnanuntana, Aasis; Ton, Quang; Kleimeyer, John; Nguyen, Joseph; Lane, Joseph // Clinical Orthopaedics & Related Research;Mar2012, Vol. 470 Issue 3, p927 

    Background: Fracture leads to local and systemic catabolic physiologic changes. As teriparatide is an agent used to treat osteoporosis in patients with fragility fractures, it is unclear whether teriparatide treatment alters bone mineral density (BMD) and bone markers when given to patients with...

  • Recombinant human parathyroid hormone. Reeve, Jonathan // BMJ: British Medical Journal (International Edition);2/23/2002, Vol. 324 Issue 7335, p435 

    Editorial. Reports that the United States Food & Drug Administration voted in favor of the recombinant parathyroid hormone for the treatment of menopausal osteoporosis. Finding that the hormone injections increase bone mass and strength; Description of how data from animal studies helped...

  • Bears, bones and osteoporosis.  // Active Living;Nov2006, Vol. 15 Issue 6, p29 

    The article discusses a review by the Scientific Advisory Council of Osteoporosis Canada which concluded that treatment with parathyroid hormone could be effective for osteoporosis. Parathyroid hormone is produced by black bears after hibernation to overcome bone loss generated by several months...

  • Review: Parathyroid hormone increases lumbar spine bone mineral density and decreases vertebral fractures in osteoporosis. Cummings, Steven R. // ACP Journal Club;Jul/Aug2003, Vol. 139 Issue 1, p11 

    Provides information on the study on parathyroid hormone (PTH) for treatment of osteoporosis. Types of osteoporosis; Details on PTH treatment; Need for determining the effect of combining antiresorptives and PTH.

  • New options in treating osteoporosis. LoBuono, Charlotte // Drug Topics;5/5/2003 Supplement, Vol. 147 Issue 9, p9S 

    Focuses on the alternative option in the treatment of osteoporosis called teriparatide, a recombinant form of human parathyroid hormone. Recommended administration; Most common adverse effects; Other therapies for osteoporosis.

  • Teriparatide (hPTH-[1-34]). Ashworth, L.E. // Formulary;Mar2002, Vol. 37 Issue 3, p129 

    Examines the efficacy of teriparatide (hPTH-[1-34]) in treating osteoporosis. Pharmacological properties of teriparatide; Increase in the total-body bone mass density; Adverse effects of the drug.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics